Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.

Saved in:
Bibliographic Details
Title: Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.
Authors: Hsu PC; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Huang CY; Department of Pulmonary and Critical Care, Buddhist Tzu Chi General Hospital, New Taipei City, Taiwan., Lin YC; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Oncology, Department of Respiratory and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi County, Taiwan.; Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi County, Taiwan., Lee SH; Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan., Chiu LC; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Wu CE; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Kuo SC; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Ju JS; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Huang AC; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Ko HW; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Wang CC; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan., Yang CT; Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan, Taiwan.; Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Source: Frontiers in oncology [Front Oncol] 2023 Oct 03; Vol. 13, pp. 1249106. Date of Electronic Publication: 2023 Oct 03 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2023.1249106